Target intelligence / Profile preview

HIV-1 envelope glycoprotein 41 membrane-proximal external region (MPER)

Target
MPER
Molecular classification
Viral envelope protein, Type I viral fusion protein subunit
01

Overview

The HIV-1 envelope glycoprotein 41 membrane-proximal external region (MPER) is a highly conserved, tryptophan-rich segment of the gp41 transmembrane subunit located immediately adjacent to the viral lipid bilayer (UniProt: P04578). It plays a critical role in the viral entry process by facilitating the fusion of the HIV-1 envelope with the host cell plasma membrane during the final stages of infection. Because its sequence is remarkably stable across diverse HIV-1 clades, MPER is a primary target for the development of broadly neutralizing antibodies (bNAbs) and universal HIV vaccines (PubMed: 15661915). Antibodies such as 2F5, 4E10, and 10E8 bind to this region, effectively neutralizing the virus by arresting the conformational changes required for membrane fusion. However, the MPER is often physically shielded or partially buried within the viral membrane, making it difficult for the immune system to access. Additionally, some MPER-targeting antibodies exhibit polyreactivity with host lipids, which presents a significant challenge in designing safe and effective immunogens that do not trigger autoimmune responses (PubMed: 24089451).

Other names
Membrane-proximal external regiongp41 MPERHIV-1 gp41 MPERgp41 membrane-proximal region
02

Mechanism of action

Binding to the highly conserved MPER domain of the gp41 subunit to inhibit the transition of the fusion machinery from the pre-hairpin intermediate to the six-helix bundle, thereby preventing the fusion of the viral envelope with the host cell membrane (PubMed: 22114446, 23153335).

03

Biological functions

Viral entryMembrane fusionViral-host cell attachment
04

Disease associations

HIV-1 infectionAcquired immunodeficiency syndrome (AIDS)
05

Safety considerations

Potential for autoreactivity due to lipid-binding propertiesCross-reactivity with host phospholipids such as cardiolipinLow immunogenicity and shielding by the viral glycan canopyRisk of inducing anti-phospholipid syndrome-like antibodies
06

Interacting drugs

2F5 (monoclonal antibody)

5 more in the full profile.

07

Biomarkers

Anti-MPER antibody titerHIV-1 viral loadCD4+ T-cell count

Beyond the preview

Go deeper on HIV-1 envelope glycoprotein 41 membrane-proximal external region (MPER).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 envelope glycoprotein 41 membrane-proximal external region (MPER).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call